Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Secukinumab in Active Psoriatic Arthritis
2012-004439-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriatic arthritis (PsA), plaque psoriasis and psoriasis (4 arms), sponsored by Novartis. Primary endpoint: ACR20 response at Week 24. Started Dec 2012; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2012-004439-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004439-22.